- Investing Ideas
- U.S. Pharmaceuticals & Biotech High ROE Growth Engines
U.S. Pharmaceuticals & Biotech High ROE Growth Engines
Results
15
15 companies
Incyte
Market Cap: US$25.8b
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
INCY
US$127.81
7D
6.4%
1Y
50.3%
Exelixis
Market Cap: US$13.3b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$54.08
7D
5.5%
1Y
40.0%
ACADIA Pharmaceuticals
Market Cap: US$5.1b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$29.50
7D
4.5%
1Y
14.6%
CareDx
Market Cap: US$2.4b
Provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally.
CDNA
US$48.61
7D
7.3%
1Y
274.8%
ADMA Biologics
Market Cap: US$2.2b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$9.84
7D
3.9%
1Y
-44.7%
Innoviva
Market Cap: US$1.5b
Operates as a biopharmaceutical company in the United States and internationally.
INVA
US$21.07
7D
-0.6%
1Y
4.5%
MeiraGTx Holdings
Market Cap: US$1.4b
A clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases.
MGTX
US$14.34
7D
6.1%
1Y
83.1%
Zevra Therapeutics
Market Cap: US$706.1m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$11.87
7D
4.9%
1Y
25.7%
CorMedix
Market Cap: US$641.5m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$8.20
7D
8.8%
1Y
-40.1%
Q32 Bio
Market Cap: US$472.1m
A clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.
QTTB
US$15.97
7D
5.4%
1Y
736.1%
Compugen
Market Cap: US$251.0m
A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
CGEN
US$2.62
7D
8.5%
1Y
80.3%
Protalix BioTherapeutics
Market Cap: US$191.8m
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
PLX
US$2.38
7D
7.2%
1Y
43.4%
Vaxart
Market Cap: US$126.2m
A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform.
VXRT
US$0.52
7D
-5.2%
1Y
48.4%
Rallybio
Market Cap: US$88.2m
A clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases.
RLYB
US$16.83
7D
-0.9%
1Y
236.1%
Actinium Pharmaceuticals
Market Cap: US$35.2m
Develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
ATNM
US$1.10
7D
5.8%
1Y
-36.8%